{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:11:16Z","timestamp":1774307476930,"version":"3.50.1"},"reference-count":35,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mach-Gaensslen Foundation of Canada and the College of Medicine, University of Saskatchewan"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Small intestine adenocarcinoma is a rare cancer. The current study aims to determine the outcomes of patients with small intestine adenocarcinoma in a Canadian province. Methods: This retrospective population-based cohort study assessed patients with small intestine adenocarcinoma who were diagnosed from 2008 to 2017 in Saskatchewan. A Cox proportional multivariate regression analysis was performed to determine the correlation between survival and exploratory factors. Results: 112 eligible patients with a median age of 73 years and M:F of 47:53 were identified. Overall, 75% had a comorbid illness, and 45% had a WHO performance status &gt;1. Of the 112 patients, 51 (46%) had early-stage disease and 61 (54%) had advanced-stage disease. The median overall survival (mOS) was as follows: stage one, 59 months; stage two, 30 months; stage three, 20 months; and stage four, 3 months (p &lt; 0.001). The median disease-free survival of patients with stage three disease who received adjuvant chemotherapy was 26 months (95% CI:23.1\u201328.9) vs. 4 months (0.0\u20139.1) with observation (p = 0.04). Patients who received chemotherapy for advanced disease had a mOS of 10 months (3.5\u201316.5) vs. 2 months (0.45\u20133.6) without chemotherapy (p &lt; 0.001). In the multivariate analysis, stage four disease, hazard ratio (HR), 3.20 (1.84\u20135.40); WHO performance status &gt;1, HR, 2.22 (1.42\u20133.45); lack of surgery, HR, 2.10 (1.25\u20133.50); and a neutrophil:lymphocyte ratio of &gt;4.5, HR, 1.72 (1.10\u20132.71) were significantly correlated with inferior survival. Conclusions: Most patients with small intestine adenocarcinoma were diagnosed with advanced-stage disease. Advanced-stage disease, poor performance status, lack of surgery and a baseline neutrophil:lymphocyte ratio &gt;4.5 were correlated with inferior survival.<\/jats:p>","DOI":"10.3390\/cancers14112581","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T22:04:06Z","timestamp":1653429846000},"page":"2581","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of Patients with Small Intestine Adenocarcinoma in a Canadian Province: A Retrospective Multi-Center Population-Based Cohort Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8655-4642","authenticated-orcid":false,"given":"Emma","family":"Yanko","sequence":"first","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duc","family":"Le","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"},{"name":"Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shazia","family":"Mahmood","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"},{"name":"Allan Blair Cancer Centre, University of Saskatchewan, Regina, SK S4T 7T1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Nathan","family":"Ginther","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"},{"name":"Department of Surgery, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haji Ibraheem","family":"Chalchal","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"},{"name":"Allan Blair Cancer Centre, University of Saskatchewan, Regina, SK S4T 7T1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rani","family":"Kanthan","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"},{"name":"Department of Pathology, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Haider","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"},{"name":"Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Zaidi","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"},{"name":"Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorie-Anna","family":"Dueck","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"},{"name":"Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-7695","authenticated-orcid":false,"given":"Osama","family":"Ahmed","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"},{"name":"Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branawan","family":"Gowrishankar","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"},{"name":"Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2099-698X","authenticated-orcid":false,"given":"Shahid","family":"Ahmed","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"},{"name":"Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1111\/j.1572-0241.2006.00854.x","article-title":"Incidence and management of primary malignant small bowel cancers: A well-defined French population study","volume":"101","author":"Lepage","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cncr.20404","article-title":"Adenocarcinoma of the small bowel: Presentation, prognostic factors, and outcome of 217 patients","volume":"101","author":"Dabaja","year":"2004","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","article-title":"Small bowel cancer in the United States: Changes in epidemiology, treatment, and survival over the last 20 years","volume":"249","author":"Bilimoria","year":"2009","journal-title":"Ann. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7819-6-12","article-title":"Prognostic factors in primary adenocarcinoma of the small intestine: 13-year single institution experience","volume":"6","author":"Chaiyasate","year":"2008","journal-title":"World J. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00432-009-0668-3","article-title":"Adenocarcinoma of the small bowel at a single Korean institute: Management and prognosticators","volume":"136","author":"Moon","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s12029-011-9290-0","article-title":"Prognostic clinicopathological factors after curative resection of small bowel adenocarcinoma","volume":"43","author":"Inoue","year":"2012","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1007\/s10350-004-6457-9","article-title":"Adenocarcinoma of the small bowel: A study of 37 cases with emphasis on histologic prognostic factors","volume":"45","author":"Abrahams","year":"2002","journal-title":"Dis. Colon. Rectum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clcc.2019.05.002","article-title":"Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma","volume":"18","author":"Huffman","year":"2019","journal-title":"Clin. Colorectal. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7440","DOI":"10.21037\/apm-21-600","article-title":"Specific survival nomograms based on SEER database for small intestine adenocarcinoma","volume":"10","author":"Wang","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10147-020-01813-8","article-title":"Nomograms predict survival of patients with small bowel adenocarcinoma: A SEER-based study","volume":"26","author":"Zheng","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"759162","DOI":"10.3389\/fsurg.2021.759162","article-title":"Metastasis Pattern and Survival Analysis in Primary Small Bowel Adenocarcinoma: A SEER-Based Study","volume":"8","author":"Gu","year":"2021","journal-title":"Front. Surg."},{"key":"ref_12","first-page":"90","article-title":"Recent advances in the management of adenocarcinoma of the small intestine","volume":"3","author":"Overman","year":"2009","journal-title":"Gastrointest Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1080\/00365521.2017.1356932","article-title":"Primary small bowel adenocarcinoma: Current view on clinical features, risk and prognostic factors, treatment and outcome","volume":"52","author":"Lech","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100132","DOI":"10.1016\/j.esmoop.2021.100132","article-title":"Metastatic small bowel adenocarcinoma: Role of metastasectomy and systemic chemotherapy","volume":"6","author":"Bhamidipati","year":"2021","journal-title":"ESMO Open"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejso.2018.11.012","article-title":"Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study","volume":"45","author":"Rompteaux","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/bjc.2017.338","article-title":"The characteristics and outcomes of small bowel adenocarcinoma: A multicentre retrospective observational study","volume":"117","author":"Sakae","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2693::AID-CNCR14>3.0.CO;2-U","article-title":"The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: Review of the National Cancer Data Base, 1985\u20131995","volume":"86","author":"Howe","year":"1999","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9453","DOI":"10.1038\/s41598-018-27896-y","article-title":"The dynamic change of neutrophil to lymphocyte ratio can predict clinical outcome in stage I-III colon cancer","volume":"8","author":"Li","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ejso.2018.02.003","article-title":"The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients","volume":"44","author":"Miyamoto","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"19673","DOI":"10.1038\/s41598-019-56218-z","article-title":"Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer","volume":"9","author":"Howard","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Vano, Y.A., Oudard, S., By, M.A., T\u00eatu, P., Thibault, C., Aboudagga, H., Scott\u00e9, F., and Elaidi, R. (2018). Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195042"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00428-015-1787-7","article-title":"The immune response in cancer: From immunology to pathology to immunotherapy","volume":"467","author":"Giraldo","year":"2015","journal-title":"Virchows Arch."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/fon.09.136","article-title":"Role of systemic inflammatory response in predicting survival in patients with primary operable cancer","volume":"6","author":"Roxburgh","year":"2010","journal-title":"Future Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_25","first-page":"S1533-002800129-8","article-title":"Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers","volume":"1","author":"Yu","year":"2021","journal-title":"Clin. Colorectal Cancer."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjsurg.2009.05.037","article-title":"A single-institution experience with 491 cases of small bowel adenocarcinoma","volume":"199","author":"Halfdanarson","year":"2010","journal-title":"Am. J. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3892\/mco.2013.150","article-title":"The effects of chemotherapy on primary small bowel cancer: A retrospective multicenter observational study in Japan","volume":"1","author":"Mizushima","year":"2013","journal-title":"Mol. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","article-title":"A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma","volume":"23","author":"Xiang","year":"2012","journal-title":"Anticancer Drugs."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s10147-017-1138-6","article-title":"A phase II study of 5-fluorouracil\/L-leucovorin\/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma","volume":"22","author":"Horimatsu","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00268-005-7898-6","article-title":"Prognostic factors of primary small bowel adenocarcinoma: Univariate and multivariate analysis","volume":"30","author":"Wu","year":"2006","journal-title":"World J. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cncr.29840","article-title":"Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score-matched analysis","volume":"122","author":"Ecker","year":"2016","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3109\/02841860903490051","article-title":"Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine","volume":"49","author":"Overman","year":"2010","journal-title":"Acta Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/DCR.0000000000000562","article-title":"Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer","volume":"59","author":"Young","year":"2016","journal-title":"Dis. Colon Rectum"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.7150\/jca.16606","article-title":"A Retrospective Review of Chemotherapy for Patients with Small Bowel Adenocarcinoma in British Columbia","volume":"7","author":"Duerr","year":"2016","journal-title":"J. Cancer"},{"key":"ref_35","first-page":"CD005202","article-title":"Adjuvant chemotherapy for small intestine adenocarcinoma","volume":"18","author":"Singhal","year":"2007","journal-title":"Cochrane Database Syst Rev."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2581\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:17:30Z","timestamp":1760138250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14112581"],"URL":"https:\/\/doi.org\/10.3390\/cancers14112581","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]}}}